Founder & Executive Chairperson at Biocon
I like to challenge myself and reinvent my business. Around 1996, I decided to apply our fermentation platforms to pharmaceuticals. We successfully produced statins, capturing a significant share of the global active pharmaceutical ingredient market, and then began targeting recombinant human insulin.
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Use this answer in your research, article, or academic work
